Randomized controlled ferret study to assess the direct impact of 2008-09 trivalent inactivated influenza vaccine on A(H1N1)pdm09 disease risk

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Skowronski, Danuta M ^a,b   Hamelin, Marie Eve ^c,d   De Serres, Gaston ^c,d,e   Janjua, Naveed Z ^a,b   Li, Guiyun ^a   Sabaiduc, Suzana ^a,b   Bouhy, Xavier ^c   Couture, Christian ^f   Leung, Anders ^g   Kobasa, Darwyn ^g,h   Embury Hyatt, Carissa ⁱ   De Bruin, Erwin ^j   Balshaw, Robert ^a,b,k   Lavigne, Sophie ^f   Petric, Martin ^a,b   Koopmans, Marion ^j,l   Boivin, Guy ^c,d  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^f LAVAL UNIVERSITY   (Canada)

^g PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ CANADIAN FOOD INSPECTION AGENCY   (Canada)

^j NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^k SIMON FRASER UNIVERSITY   (Canada)

^l ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INFLUENZA VACCINE; PLACEBO; VIRUS ANTIBODY;

2009 H1N1 INFLUENZA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CANADA; CLINICAL FEATURE; CONTROLLED STUDY; DRUG MANUFACTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FERRET; HEMAGGLUTINATION INHIBITION; HISTOPATHOLOGY; INFECTION RISK; INFLAMMATION; LOSS OF APPETITE; LUNG; MALE; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PNEUMONIA; RANDOMIZATION; SCORING SYSTEM; VIRUS LOAD; WEIGHT REDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FERRETS; HEMAGGLUTINATION TESTS; IMMUNOHISTOCHEMISTRY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICROARRAY ANALYSIS; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, INACTIVATED;

EID: 84899902256     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086555     Document Type: Article

References (77)

1. Skowronski DM, De Serres G, Crowcroft NS, Janjua NZ, Boulianne N, et al. (2010) Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during spring-summer 2009: Four observational studies from Canada. PLoS Med 7(4): e1000258. doi:10.1371/journal.pmed.1000258.
2. Janjua NZ, Skowronski DM, Hottes TS, Osei W, Adams E, et al. (2010) Seasonal influenza vaccine and increased risk of pandemic A/H1N1-related illness: first detection of the association in British Columbia, Canada. Clin Infect Dis 51: 1017-1027.
3. Crum-Cianflone NF, Blair PJ, Faix D, Arnold J, Echols S, et al. (2009) Clinical and epidemiologic characteristics of an outbreak of novel H1N1 (swine origin) influenza A virus among United States military beneficiaries. Clin Infect Dis 49: 1801-1810.
4. Tsuchihashi Y, Sunagawa T, Yahata Y, Takahashi H, Toyokawa T, et al. (2012) Association between seasonal influenza vaccination in 2008-2009 and pandemic influenza A (H1N1) 2009 infection among school students from Kobe, Japan, April-June 2009. Clin Infect Dis 54: 381-383.
5. Gilca R, Deceuninck G, De Serres G, Boulianne N, Sauvageau C, et al. (2011) Effectiveness of pandemic H1N1 vaccine against influenza-related hospitalization in children. Pediatrics 128: e1084-1091.
6. Centers for Disease Control and Prevention (CDC) (2009) Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May-June 2009. MMWR Morb Mortal Wkly Rep 58: 1241-1245.
7. Iuliano AD, Reed C, Guh A, Desai M, Dee DL, et al. (2009) Notes from the field: outbreak of 2009 pandemic influenza A (H1N1) virus at a large public university in Delaware, April-May 2009. Clin Infect Dis 49: 1811-1820.
8. Kelly HA, Grant KA, Fielding JE, Carville KS, Looker CO, et al. (2011) Pandemic influenza H1N1 2009 infection in Victoria, Australia: no evidence for harm or benefit following receipt of seasonal influenza vaccine in 2009. Vaccine 29: 6419-6426.
9. Mahmud SM, Van Caeseele P, Hammond G, Kurbis C, Hilderman T, et al. (2012) No association between 2008-09 influenza vaccine and influenza A(H1N1)pdm09 virus infection, Manitoba, Canada, 2009. Emerg Infect Dis 18: 801-810.
10. Garcia-Garcia L, Valdespino-Gómez JL, Lazcano-Ponce E, Jimenez-Corona A, Higuera-Iglesias A, et al. (2009) Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case control study in Mexico City. BMJ 339: b3928.
11. Echevarría-Zuno S, Mejía-Aranguré JM, Mar-Obeso AJ, Grajales-Muñiz C, Robles-Pérez E, et al. (2009) Infection and deaths from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 374: 2072-2079.
12. Cowling BJ, Ng S, Ma ES, Cheng CK, Wai W, et al. (2010) Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clin Infect Dis 51: 1370-1379. Available: http://cid.oxfordjournals.org/content/51/12/1370.long. Accessed 2013 Dec 12.
13. Skowronski DM, Janjua NZ, Hottes TS, De Serres G (2011) Mechanism for seasonal vaccine effect on pandemic H1N1 risk remains uncertain. Clin Infect Dis 52: 831-832. Available: http://cid.oxfordjournals.org/content/52/6/831.long. Accessed 2013 Dec 12.
14. Chen GL, Min J-Y, Lamirande EW, Santos C, Jin H, et al. (2011) Comparison of a live attenuated 2009 H1N1 vaccine with seasonal influenza vaccines against 2009 pandemic H1N1 virus infection in mice and ferrets. J Infect Dis 203: 930-936.
15. Del Giudice G, Stittelaar KJ, van Amerongen G, Simon J, Osterhaus AD, et al. (2009) Seasonal influenza vaccine provides priming for A/H1N1 immunization. Sci Transl Med 1(12): 12re1.
16. Kobinger GP, Meunier I, Patel A, Pillet S, Gren J, et al. (2010) Assessment of the efficacy of commercially available and candidate vaccines against a pandemic H1N1 2009 virus. J Infect Dis 201: 1000-1006.
17. Ellebedy AH, Ducatez MF, Duan S, Stigger-Rosser E, Rubrum AM, et al. (2011) Impact of prior seasonal influenza vaccination and infection on pandemic A(H1N1) influenza virus replication in ferrets. Vaccine 29: 3335-3339.
18. van den Brand JM, Kreijtz JH, Bodewes R, Stittelaar KJ, van Amerongen G, et al. (2011) Efficacy of vaccination with different combinations of MF59-adjuvanted and non-adjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets. J Virol 85: 2851-2858.
19. Pearce MB, Belser JA, Houser KV, Katz JM, Tumpey TM (2011) Efficacy of seasonal live attenuated influenza vaccine against virus replication and transmission of a pandemic 2009 H1N1 virus in ferrets. Vaccine 29: 2887-2894.
20. World Health Organization. WHO recommendations on the composition of influenza virus vaccines. Available: http://www.who.int/influenza/vaccines/ virus/recommendations/en/index.html Accessed 2013 Dec 12.
21. Skowronski DM, Hamelin M-E, Janjua NZ, De Serres G, Gardy JL, et al. (2012) Cross-lineage influenza B and heterologous influenza A antibody responses in vaccinated mice: immunologic interactions and B/Yamagata dominance. PLoS One 7(6): e38929. doi: 10.1371/journal.pone.0038929.
22. Hamelin ME, Baz M, Abed Y, Couture C, Joubert P, et al. (2010) Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. PLoS Pathog 6: e1001015. doi: 10.1371/journal.ppat.1001015.
23. Abed Y, Pizzorno A, Hamelin ME, Leung A, Joubert P, et al. (2011) The 2009 pandemic H1N1 D222G hemagglutinin mutation alters receptor specificity and increases virulence in mice but not in ferrets. J Infect Dis 204: 1008-1016. doi: 10.1093/infdis/jir483.
24. World Health Organization (2011) Global Influenza Surveillance Network Manual for the laboratory diagnosis and virological surveillance of influenza. Available: http://whqlibdoc.who.int/publications/2011/9789241548090-eng.pdf Accessed 2013 Dec 12.
25. IDEXX product brochure. Available: http://www.idexx.com/pubwebresources/ pdf/en-us/livestock-poultry/influenza-a-ab-test-sheet.pdf. Accessed 2013 Dec 12.
26. Koopmans M, de Bruin E, Godeke GJ, Friesema I, van Gageldonk R, et al. (2012) Profiling of humoral immune responses to influenza viruses by using protein microarray. Clin Microbiol Infect 18: 797-807.
27. Hatakeyama S, Sakai-Tagawa Y, Kiso M, Goto H, Kawakami C, et al. (2005) Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J Clin Microbiol 43: 4139-4146. Available: http://jcm.asm.org/content/43/8/4139.long Accessed 12 December 2013.
28. Hamelin ME, Couture C, Sackett MK, Boivin G (2007) Enhanced lung disease and Th2 response following human metapneumovirus infection in mice immunized with the inactivated virus. J Gen Virol 88: 3391-3400. Available: http://vir.sgmjournals.org/content/88/12/3391.long Accessed 2013 Dec 12.
29. Svitek N, von Messling V (2007) Early cytokine mRNA expression profiles predict Morbillivirus disease outcome in ferrets. Virology 362: 404-410. (Pubitemid 46695743)
30. Nakata M, Itou T, Sakai T (2008) Molecular cloning and phylogenetic analysis of inflammatory cytokines of the ferret (Mustela putorius furo). J Vet Med Sci 70: 543-550. (Pubitemid 352008810)
31. Danesh A, Cameron CM, León AJ, Ran L, Xu L, et al. (2011) Early gene expression events in ferrets in response to SARS coronavirus infection versus direct interferon-alpha2b stimulation. Virology 409: 102-112.
32. Pfaffl MW (2001) A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res 29(9): e45.
33. Cowling BJ, Ng S, Ma ES, Fang VJ, So HC, et al. (2012) Protective efficacy against pandemic influenza of seasonal influenza vaccination in children in Hong Kong: a randomized controlled trial. Clin Infect Dis 55: 695-702. doi: 10.1093/cid/cis518.
34. Belser JA, Katz JM, Tumpey TM (2011) The ferret as a model organism to study influenza A virus infection. Dis Model Mech 4: 575-579. doi: 10.1242/dmm.007823.
35. Bodewes R, Kreijtz JHCM, Baas C, Geelhoed-Mieras MM, de Mutsert G, et al. (2009) Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS One 4: e5538. Doi: 10.1371/journal.pone.0005538.
36. Bodewes R, Kreijtz JH, Rimmelzwaan GF (2009) Yearly influenza vaccinations: a double-edged sword? Lancet Infect Dis 9: 784-788.
37. Kelly H, Barry S, Laurie K, Mercer G (2010) Seasonal influenza vaccination and the risk of infection with pandemic influenza: a possible illustration of nonspecific temporary immunity following infection. Euro Surveill 15(47): pii: 19722.
38. Stephenson JR (2005) Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ 83: 308-314.
39. Midgley CM, Bajwa-Joseph M, Vasanawathana S, Limpitikul W, Wills B, et al. (2001) An in-depth analysis of original antigenic sin in dengue virus infection. J Virol 85: 410-421.
40. Monsalvo AC, Batalle JP, Lopez MF, Krause JC, Klemenc J, et al. (2011) Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med 17: 195-99.
41. To KKW, Zhang AJX, Hung IFN, Xu T, Ip WCT, et al. (2012) High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza. Clin Vaccine Immunol 19: 1012. DOI: 10.1128/CVI.00081-12.
42. Vincent AL, Lager KM, Janke BH, Gramer MR, Richt JA (2008) Failure of protection and enhanced pneumonia with a US H1N2 swine influenza virus in pigs vaccinated with an inactivated classical swine H1N1 vaccine. Vet Microbiol 126: 310-323. (Pubitemid 350199605)
43. Gauger PC, Vincent AL, Loving CL, Lager KM, Janke BH, et al. (2011) Enhanced pneumonia and disease in pigs vaccinated with an inactivated human-like (d-cluster) H1N2 vaccine and challenged with pandemic 2009 H1N1 influenza virus. Vaccine 29: 2712-2719.
44. Gauger PC, Vincent AL, Loving CL, Henningson JN, Lager KM, et al. (2012) Kinetics of lung lesion development and pro-inflammatory cytokine response in pigs with vaccine-associated enhanced respiratory disease induced by challenge with pandemic (2009) A/H1N1 influenza virus. Vet Pathol 49: 900-912.
45. Vincent AL, Ma W, Lager KM, Richt JA, Janke BH, et al. (2012) Live attenuated influenza vaccine provides superior protection from heterologous infection in pigs with maternal antibodies without inducing vaccine-associated enhanced respiratory disease. J Virol 86(19): 10597-10605.
46. Gotoff R, Tamura M, Janus J, Thompson J, Wright P, et al. (1994) Primary influenza A virus infection induces cross-reactive antibodies that enhance uptake of virus into Fc receptor-bearing cells. J Infect Dis 169: 200-203. doi: 10.1093/infdis/169.1.200.
47. Ochiai H, Kurokawa M, Kuroki Y, Niwayama S (1990) Infection enhancement of influenza A H1 subtype viruses in macrophage-like P388D1 cells by cross-reactive antibodies. J Med Virol 30: 258-265. doi: 10.1002/jmv.1890300406. (Pubitemid 20203828)
48. Ochiai H, Kurokawa M, Hayashi K, Niwayama S (1988) Antibody-mediated growth of influenza A NWS virus in macrophagelike cell line P388D1. J Virol 62: 20-26. (Pubitemid 18050787)
49. Ochiai H, Kurokawa M, Matsui S, Yamamoto T, Kuroki Y, et al. (1992) Infection enhancement of influenza A NWS virus in primary murine macrophages by anti-hemagglutinin monoclonal antibody. J Med Virol 36: 217-221. doi: 10.1002/jmv.1890360312.
50. Dutry I, Yen H, Lee H, Peiris M, Jaume M (2011) Antibody-dependent enhancement (ADE) of infection and its possible role in the pathogenesis of influenza. BMC Proc (Suppl 1): P62.
51. Khurana S, Loving CL, Manischewitz J, King LR, Gauger PC, et al. (2013) Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Science Translational Medicine 5: 1-10. DOI: 10.1126/scitranslmed.3006366.
52. Crowe JE (2013) Universal flu vaccines: primum non nocere. Science Translational Medicine 5: 1-3. DOI: 10.1126/scitranslmed.3007118.
53. Uno S, Kimachi K, Kei J, Miyazaki K, Oohama A, et al (2011). Effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the influenza pandemic H1N1 2009 vaccine: a randomized controlled trial. Microbiol Immunol 55: 783-89.
54. Ohfuji S, Fukushima W, Deguchi M, Kawabata K, Yoshida H, et al. (2011). Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine among pregnant women: lowered antibody response by prior seasonal vaccination. J Infect Dis 203: 1301-8.
55. Choi YS, Baek YH, Kang W, Nam SJ, Lee J, et al (2011). Reduced antibody responses to the pandemic (H1N1) 2009 vaccine after recent seasonal influenza vaccination. Clin Vaccine Immunol 18: 1519-23. Doi: 10.1128/CVI.05053-11. Epub 2011 Aug 3.
56. Huijskens EG, Reimerink J, Mulder PG, van Beek J, Meijer A, et al (2013). Profiling of humoral response to influenza A (H1N1)pdm09 infection and vaccination measured by a protein microarray in persons with and without history of seasonal vaccination. PLoS One 8: e54890. Doi: 10.1371/journal.pone.0054890. Available at : http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0054890 Accessed 12 December 2013.
57. Qiu C, Huang Y, Wang Q, Tian D, Zhang W, et al (2012). Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine. CID 54: 17-24.
58. McElhaney JE, Hooton JW, Hooton N, Bleackley RC (2005) Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults. Vaccine 23: 3294-3300. (Pubitemid 40523123)
59. Oldfield WLG, Kay AB, Larché M (2001) Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol 167: 1734-1739. (Pubitemid 32703177)
60. Spellberg B, Edwards JE Jr (2001) Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis 32: 76-102. (Pubitemid 32150953)
61. Ryzhakov G, Lai CC, Blazek K, To KW, Hussell T, et al. (2011) IL-17 boosts proinflammatory outcomes of antiviral response in human cells. J Immunol 187: 5357-5362.
62. Crowe CR, Chen K, Pociask DA, Alcorn JF, Krivich C, et al. (2009) Critical role of IL-17RA in immunopathology of influenza infection. J Immunol 183: 5301-5310.
63. McKinstry KK, Strutt TM, Buck A, Curtis JD, Dibble JP, et al. (2009) IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol 182: 7353-7363 doi: 10.4049/jimmunol.0900657. Available: http://www.jimmunol.org/content/182/12/7353 Accessed 2013 Dec 12.
64. de Jong JC, Palache AM, Beyer WEP, Rimmelzwaan GF, Boon ACM, et al. (2003) Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 115: 63-73.
65. Katz JM, Hancock K, Xu X (2011) Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti-Infect. Ther. 9: 669-83. Doi: 10.1586/eri.11.51.
66. Potter CW, Shore SL, McLaren C, Stuart-Harris C (1972) Immunity to influenza in ferrets. II. Influence of adjuvants on immunization. Br J Exp Path 153: 168-79.
67. Potter CW, McLaren C, Shore SL (1973) Immunity to influenza in ferrets. V. Immunization with inactivated virus in adjuvant 65. J Hyg 71: 97-106.
68. Potter CW, Oxford JS, Shore SL, McLaren C, Stuart-Harris C (1972) Immunity to influenza in ferrets. I. Response to live and killed virus. Br J exp Path 53: 153-67.
69. McLaren C, Potter CW (1974) Immunity to influenza in ferrets. VII. Effect of previous infection with heterotypic and heterologous influenza viruses on the response of ferrets to inactivated influenza virus vaccines. J Hyg 72: 91-100.
70. Sweet C, Stephen J, Smith H (1974) Immunization of ferrets against influenza: a comparison of killed ferret grown and egg grown virus. Br J Exp Path 55: 296-304.
71. McLaren C, Potter CW, Jennings R (1974) Immunity to influenza in Ferrets X. Intranasal immunization of ferrets with inactivated influenza A virus vaccines. Infect Immun 9: 985-90.
72. Laurie KL, Carolan LA, Middleton D, Lowther S, Kelso A, et al. (2010) Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model. J Infect Dis 202: 1011-19.
73. Rockman S, Middleton DJ, Pearse MJ, Barr IG, Lowther S, et al. (2012) Control of pandemic (H1N1) 2009 influenza virus infection of ferret lungs by non-adjuvant-containing pandemic and seasonal vaccines. Vaccine 30: 3618-23.
74. Langley JM, Vanderkooi OG, Garfield HA, Hebert J, Chandrasekaran V, et al. (2012) Immunogenicity and safety of 2 dose levels of a thimerosal-free trivalent seasonal influenza vaccine in children aged 6-35 months: a randomized, controlled trial. J Pediatric Infect Dis Soc 1(1): 55-63. doi:10.1093/jpids/ pis012.
75. National Advisory Committee on Immunization (NACI) (2009) Statement on seasonal trivalent inactivated influenza vaccine (TIV) for the 2009-2010 season. Can Commun Dis Rep 35: 1-41. Available: http://www.phac-aspc.gc.ca/publicat/ ccdr-rmtc/09vol35/acs-dcc-6/index-eng.php Accessed 2013 Dec 12.
76. Houser KV, Katz JM, Tumpey TM (2013) Seasonal trivalent inactivated influenza vaccine does not protect against newly emerging variants of influenza A (H3N2v) virus in ferrets. J Virol 87:1261-1263. doi:10.1128/JVI.02625-12. Available: http://jvi.asm.org/content/87/2/1261.full.pdf Accessed 2013 Dec 12.
77. Simonsen L, Spreeuwenberg P, Lustig R, Taylor RJ, Fleming DM, et al. (2013) Global mortality estimates for the 2009 influenza pandemic from the GlaMOR Project: a modeling study. PLOS Med 10(11): e1001558. Doi:10.1371/journal.pmed.1001558. Available at: http://www.plosmedicine.org/ article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001558 Accessed 2013 Dec 12.